Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.50 |
| ▸ | BCKDK | O14874 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.46 |
| ▸ | BCL2 | P10415 | 1/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.46 |
| ▸ | BAD | Q92934 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6659125 | 0.89 | MAPT (0.49) | MCL1RXFP1MAPTKDM4EALDH1A1 | |
| SCHEMBL18069818 | 0.86 | MCL1 (0.48) | MCL1BCKDKRXFP1MAPTKDM4E | |
| SCHEMBL25575157 | 0.86 | MCL1 (0.48) | MCL1BCKDKRXFP1MAPTKDM4E | |
| SCHEMBL11681838 | 0.86 | KDM4E (0.57) | MCL1BCKDKRXFP1MAPTKDM4E | |
| SCHEMBL31015910 | 0.86 | MCL1 (0.48) | MCL1BCKDKRXFP1MAPTKDM4E | |
| SCHEMBL25229359 | 0.86 | MCL1 (0.48) | MCL1BCKDKRXFP1MAPTKDM4E | |
| SCHEMBL15619136 | 0.85 | MCL1 (0.53) | MCL1BCKDKRXFP1MAPTKDM4E | |
| SCHEMBL31011039 | 0.83 | MAPT (0.50) | RXFP1MAPTKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL16396278 | 0.83 | ALDH1A1 (0.51) | MAPTKDM4EALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL25810203 | 0.83 | MAPT (0.50) | RXFP1MAPTKDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759769-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMECEUTICAL INC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190248754-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMECEUTICAL INC (US) | 2019-08-15 | — | — | US | disclosed |
| EP-3268355-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10227312-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180044302-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2018-02-15 | — | — | US | disclosed |
| US-20180044302-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2018-02-15 | — | — | US | disclosed |
| WO-2016145153-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759769-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | MCL1 2251/4885BCKDK 2034/4885RXFP1 4460/4885 |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | MCL1 4406/4885BCKDK 700/4885RXFP1 1297/4885 |
| US-20180044302-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | MCL1 2251/4885BCKDK 2034/4885RXFP1 4460/4885 |
| US-20190248754-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | MCL1 2251/4885BCKDK 2034/4885RXFP1 4460/4885 |
| US-10227312-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | MCL1 2251/4885BCKDK 2034/4885RXFP1 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.